News for Adial Pharmaceuticals, Inc. (ADIL)

A.G.P./Alliance Global Partners has been selected as the exclusive placement agent for (ADIL), highlighting its involvement in facilitating the company's financ

Adial Pharmaceuticals (ADIL) has filed a proposal to sell 6.73 million shares of its common stock. This move is aimed at enabling current holders to divest thei

Adial Pharmaceuticals (ADIL) released its first-quarter financial results for 2025, revealing a cash reserve of $2.4 million as of March 31, a decline from $3.8

Adial Pharmaceuticals (ADIL) completed a crucial pharmacokinetics study for its lead drug, AD04, confirming favorable bioavailability. The company repor

Adial Pharmaceuticals (ADIL) reports a Q1 net loss of $2.2M. Stay updated on their financial performance and industry insights.

**media[626993]**

Adial Pharmaceuticals (ADIL) has announced the issuance of a new patent by the United States Patent and Trademark Office, significantly enhancing its intellectu

Shares of Twilio Inc. TWLO rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results. Twilio reported ...

Adial Pharmaceuticals (ADIL) has been granted a patent, numbered 12,274,692, by the United States Patent and Trademark Office (USPTO) on April 15, 2025. This pa

**media[611636]**

GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( ADIL) (”œAdial” or the ”œCompany”), a clinical-stage biopharmaceutical

**media[556929]**

FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory re

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence GLEN AL

**media[482153]**

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adial Pharmaceuticals reports Q3 2024 net loss of $2.2 million, with cash and cash equivalents at $5.2 million as of September 30, 2024.

Michael Useem explains what effective leaders do well.

The company has repeatedly violated accounting principles.